Patent · US Active

Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1

US7910602B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Sanofi-Aventis · FR

Inventors

Henning Steinhagen · Pocking, DE
Jochen Huber · Mittelbiberach, DE
Kurt Ritter · Heidelberg, DE
Bernard Pirard · Basel, CH
Kirsten BJERGARDE · Tucson, US
Marcel Patek · Tucson, US
Martin Smrcina · Tucson, US
Linli Wei · Bound Brook, US

Key dates

Filing date	Dec 20, 2007
Grant date	Mar 22, 2011
Priority date	—
Expiry date	Apr 20, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I)useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.